

HEMO ORGANIC LIMITED

CIN: - L24231GJ1992PLC018224

Address: - 8-A, Gulnar, Chinar - Gulnar Appt. V V Nagar Road Anand -388001

Email ID: drdineshpatel@rediffmail.com, Website: www.hemoorganic.com

Ph.No:-9426075525

Date: February 06, 2023

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sir,

Sub: Submission of Unaudited Standalone Financial Results of the Company for the quarter ended on December 31, 2022 along with Limited Review Report.

Ref: Hemo Organic Ltd (Security Id: HEMORGANIC Security Code: 524590)

In reference to captioned subject and pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the followings:


1. Unaudited Standalone Financial Results for the quarter ended on December 31, 2022;
2. Limited Review Report;

Kindly take the same on your record and disseminate the same on your website and oblige us.

Thanking You,

Yours faithfully,

For, **Hemo Organic Limited**



Dr. Dinesh Patel



Hemo Organic Limited

CIN No L24231GJ1992PLC018224
Registered Office: B-A, Gulnar, Chinar-Gulnar Appt. V V Nagar Road Anand - 388001

UNAUDITED FINANCIAL RESULTS (STAND ALONE) FOR THE QUARTER ENDED ON DECEMBER 31, 2022

(Rs. in lakhs)


PART - I

Sr. No.	Particulars	Quarter ended			Nine Month ended		Year ended
		31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	INCOME						
	(a) Revenue from operations	-	0.48	-	0.48	0.68	0.68
	(b) Other Income	-	-	-	-	-	-
	Total Income	-	0.48	-	0.48	0.68	0.68
II.	EXPENSES						
	(a) Purchases of Stock-in-trade	-	-	-	-	2.39	2.39
	(b) Changes in stock of finished goods, work-in-progress and stock-in-trade	-	0.16	-	0.16	(1.45)	(1.46)
	(c) Employee benefit expense	-	-	1.08	-	3.24	3.60
	(d) Finance costs	-	-	-	-	-	0.01
	(e) Depreciation and amortisation expense	-	-	-	-	-	-
	(f) Other expenses	-	0.58	1.26	0.58	2.00	2.38
	Total Expenses (a to g)	-	0.74	2.34	0.74	6.18	6.92
III.	Profit before exceptional items and tax (I) - (II)	-	(0.26)	(2.34)	(0.26)	(5.50)	(6.24)
IV.	Exceptional Items	-	-	-	-	-	-
V.	Profit before tax (III) - (IV)	-	(0.26)	(2.34)	(0.26)	(5.50)	(6.24)
VI.	Tax Expense						
	(a) Current tax						
	- Current year	-	-	-	-	-	-
	- Prior years	-	-	-	-	-	-
	- MAT Credit (Entitlement)	-	-	-	-	-	-
	(b) Deferred tax	-	-	-	-	-	-
	Total tax expense	-	-	-	-	-	-
VII.	Profit after tax for the period (V) - (VI)	-	(0.26)	(2.34)	(0.26)	(5.50)	(6.24)
VIII.	Other comprehensive income						
	Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Remeasurement of the defined benefit liabilities	-	-	-	-	-	-
	Equity instruments through other comprehensive income	-	-	-	-	-	-
	Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Other comprehensive income, net of tax	-	-	-	-	-	-
IX.	Total comprehensive income for the period	-	(0.26)	(2.34)	(0.26)	(5.50)	(6.24)
X.	Paid up equity share capital (Face value of Rs. 10 each)	346.59	346.59	346.59	346.59	346.59	346.59
XI.	Reserves i.e. Other Equity	-	-	-	-	-	-
XII.	Earnings per equity share (Face value of Rs. 10 each)						
	(1) Basic	-	(0.01)	(0.07)	(0.01)	(0.16)	(0.18)
	(2) Diluted	-	(0.01)	(0.07)	(0.01)	(0.16)	(0.18)

Date : 06/02/2023
Place: Anand

By order of the Board
Hemo Organic Limited


Dr. Dinesh Patel
DIN : 00481641
Managing Director



Notes : Hemo Organic Limited

- 1 The Company operates in a single segment . As per Ind AS 108 on segment reporting issued by the ICAI, the same is considered to constitute as single primary segment. Accordingly, the disclosure requirements of Ind AS 108 are not applicable.
- 2 The above standalone financial results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 6th February, 2023.
- 3 Earning per share for the quarter and year ended has been calculated as per weighted average formula and diluted Earning per share has been calculated considering proposed issue of equity shares on account of conversion of convertible securities.
- 4 Previous period figures have been regrouped and rearranged, whenever considered necessary.

By order of the Board
Hemo Organic Limited



Dineshbhai S. Patel
DIN: 00481641
Managing Director



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE
FINANCIAL RESULTS OF HEMO ORGANIC LIMITED PURSUANT TO THE REGULATION
33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS)
REGULATIONS, 2015 FOR THE PERIOD ENDED 31st Dec, 2022**

To,

The Board of Directors,
Hemo Organic Limited.

We have reviewed the accompanying statement of unaudited financial results of M/s Hemo Organic Limited for the quarter ended 31st Dec, 2022, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FCA/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, except **as specified in Qualified Opinion para.**, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis on Matter:

- 1. The closing stock has been calculated and certified by management only and we have not been provided with the basis of calculation.***
- 2. The Company has not charged depreciation on the fixed assets during the year and accordingly provision of Indian Accounting Standards relating to depreciation and Deferred Tax Asset / Liabilities have not been followed. The management represented that the amount of depreciation being negligible the same has been not been incorporated.***

Qualified Opinion:

- 1. We have not been provided with the balance confirmation or any other details for the trade receivable, trade payable & Loans and Advances receivables/payables shown in the books of accounts & in the absence of the same we are unable to confirm the balance and nature of the transaction.***
- 2. We have not been able to verify the transactional documents relating bank statements. Four out of five account are not shown to us for verification. According to the management, the other accounts are dormant and therefore the same have not been collected from bank.***

Date: 06/02/2023
Place: Ahmedabad
UDIN: 23133926BGWEKO3933

For, M A A K & Associates
(Chartered Accountants)



CA Marmik Shah
(Partner)
Mem. No.:133926